Modulation of the sympathovagal balance in drug refractory dilated cardiomyopathy, treated with permanent atrioventricular sequential pacing.
The aim of this study was to assess the long term efficacy of DDD pacing mode in selected patients with idiopathic dilated cardiomyopathy (IDCM) and drug refractory heart failure. The patients were evaluated according to the long term alteration of the sympathovagal balance (SVB). Patients with IDCM were considered eligible for DDD pacing if during temporary VDD pacing a 15% or more increase in the resting cardiac output was demonstrated. From the 29 patients studied, finally 20 patients (15M, 5F, 69 +/- 10 years) fulfilled the aforementioned criterion and therefore were considered candidates for permanent DDD pacing (NYHA class: 3.5 +/- 0.3, Ejection fraction: 27 +/- 7%, Resting cardiac index (CI) 2.6 +/- 0.4 l/min). The ECG of the patients demonstrated LBBB in 13, RBBB in 4 and RBBB + LAH in 3, with a PR interval of 232 +/- 28 ms and QRS duration of 138 +/- 15 ms. The pacemaker was programmed at 40-150 bpm, and AV delay of 105 +/- 20 ms. The lower heart rate programmed, in conjunction with the heart failure state of these patients, was responsible for essentially continuous atrial tracking, ventricular pacing. We evaluated the SVB in the pre- and post-implant periods (3rd and 6th month), using the hourly power spectral analysis (PSA) of heart rate variability during 24 hour Holter monitoring. As SVB we considered the ratio: low (0.04-0.15 Hz) to high frequency (0.15-0.40 Hz). We compared the SVB (LF/HF) during the day and night time for the pre- and post-implant periods. Post-pacing, the NYHA class was significantly improved (2.9 +/- 0.2 and 2.7 +/- 0.3 the 3rd and 6th month respectively). The mean heart rate was 78 +/- 8 bpm in the 3rd and 80 +/- 7 bpm in the 6th month postoperatively, which was lower than the 84 +/- 9 bpm preoperatively, but this difference did not reach statistical significance. During the night time the LF/HF decreased from 1.45 +/- 0.2 (LF: 7.19 +/- 0.43, HF: 4.95 +/- 0.54) in the pre-implant period to 0.9 +/- 0.09 (p < 0.001) (LF: 6.96 +/- 0.63, HF: 7.73 +/- 0.48) in the 3rd month. No further changes were observed in the 6th month (0.82 +/- 0.05, p = NS) (LF: 6.83 +/- 0.51, HF: 8.53 +/- 0.86) compared to the 3rd month. During the day time the LF/HF decreased from 1.5 +/- 0.5 (LF: 7.87 +/- 0.67, HF: 5.24 +/- 0.32) to 1.43 +/- 0.6 (p = NS) (LF: 7.34 +/- 0.71, HF: 5.24 +/- 0.42) in the 3rd month and to 1.41 +/- 0.09 in the 6th month (p = NS) (LF: 7.51 +/- 0.74, HF: 5.36 +/- 0.63). Comparing the LF/HF of day and the night time period, while in the pre-implant period there was no significant difference (1.5 +/- 0.5 vs 1.45 +/- 0.2, p = NS), the difference became significant in the 3rd (1.43 +/- 0.6 vs 0.9 +/- 0.09, p < 0.001) and 6th month (1.41 +/- 0.09 vs 0.82 +/- 0.05, p < 0.001). In conclusion, DDD pacing with individualized AV delay as an adjunct therapy could be a valuable method in selected patients with IDCM and drug refractory heart failure. DDD pacing improves the SVB over the long term. This improvement is attributed to sympathetic activity withdrawal and is more pronounced during night and less during day time.
Manolis
A G
AG
Second Department of Cardiology, Hellenic Red Cross Hospital, Athens, Greece.
Liagas
K
K
Katsivas
A
A
Vassilopoulos
C
C
Koutsogeorgis
D
D
Louvros
N
N
D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D015716:Electrocardiography, Ambulatory; D005260:Female; D006321:Heart / Q000294:innervation; D006339:Heart Rate; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D014630:Vagus Nerve / Q000503:physiopathology*